Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis.
Effects of an aqueous extract of North American ginseng on MOG((35-55))-induced EAE in mice.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Cutting Edge: Integrin α4 Is Required for Regulatory B Cell Control of Experimental Autoimmune Encephalomyelitis.
Optimizing IFN Beta - 1B Dose (Optims)
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
EFNS 2012
Genmab Announces Ofatumumab Development Plans in RRMS and NMO
Value and Efficacy of Transcranial Direct Current Stimulation in the Cognitive Rehabilitation: A Critical Review Since 2000.
Cladribine
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in relapsing-Remitting Multiple Sclerosis
[Evaluation and quantification of spasticity: a review of the clinical, biomechanical and neurophysiological methods].
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063
Generic interferon-beta
Biogen Reports Another Tecfidera PML Case
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies

Pages